Global Thrombolytic Drug Market Size By Type (Reteplase, Urokinase), By End User (Hospitals and Clinics, Ambulatory Surgical Centers), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)), By Geographic Scope And Forecast

Published Date: August - 2024 | Publisher: MIR | No of Pages: 320 | Industry: latest updates trending Report | Format: Report available in PDF / Excel Format

View Details Download Sample Ask for Discount Request Customization

Global Thrombolytic Drug Market Size By Type (Reteplase, Urokinase), By End User (Hospitals and Clinics, Ambulatory Surgical Centers), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)), By Geographic Scope And Forecast

Thrombolytic Drug Market Size And Forecast

Thrombolytic Drug Market size was valued at USD 1,091.16 Million in 2022 and is projected to reach USD 3,832.81 Million by 2030, growing at a CAGR of 17.59% from 2024 to 2030.

Thrombolytics are provided in emergency situations to break up the thrombus (blood clot) that obstructs the affected artery in order to restore blood flow to the heart. The Global Thrombolytic Drug Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Thrombolytic Drug Market Definition

The market expansion can be attributed to several factors, including the escalating prevalence of cardiovascular diseases, a growing understanding of thrombolytic drugs, and the ongoing technological progress in thrombolysis. The rising incidence of cardiovascular diseasesThere is a global trend of increasing prevalence of cardiovascular diseases. This disturbing rise can be primarily attributed to the shifting lifestyles and dietary patterns people adopt worldwide.

Also, people are becoming increasingly informed about the benefits of thrombolytic drugs in preventing heart attacks and strokes. This heightened awareness has resulted in a surge in the demand for these medications in recent times. Drug delivery systems are constantly advancing, with the continual development of innovative technologies. This progress has led to the creation of more efficient and precisely targeted drug delivery mechanisms. These systems can now deliver thrombolytic drugs directly to the intended site of action, greatly enhancing their effectiveness.

Furthermore, some thrombolytic drugs can be expensive, which may limit access for specific patient groups or healthcare systems with budget constraints. Also, strict regulations govern the use of thrombolytic drugs, and concerns about potential legal liability may influence healthcare providers’ decisions regarding their use. Also, the increasing prevalence of cardiovascular diseases, such as heart attacks and strokes, provides a significant market opportunity for thrombolytic drugs, which are vital in managing these conditions.

What's inside a
industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Thrombolytic Drug Market Attractiveness Analysis

The Global Thrombolytic Drug Market is experiencing a scaled level of attractiveness in the North American region. The North American region has a prominent presence and holds a major share of the global market. North America is anticipated to account for a significant market share of 42.66% in 2022. Thrombolytic therapy is highly effective in AIS. Recombinant tissue plasminogen activator (rt-PA), the most well-studied agent used in this setting, has demonstrated efficacy in the treatment of AIS in 9 randomized trials involving more than 6,700 patients over more than 20 years. Thrombolytic therapy with rt-PA has been shown to improve the likelihood of favorable outcomes in AIS, despite a small increased risk of serious bleeding.

Therapy is time-sensitive, with the benefits of therapy decreasing successively with longer delays from onset to treatment. The benefit is greatest when rt-PA is administered within the first 3 hours after symptom onset, with a less robust risk-vs-benefit balance up to 4.5 hours. Treatment benefits of rt-PA are preserved across the spectrum of age and clinical severity of disabling deficits. The most serious risks of thrombolytic therapy are intracranial hemorrhage (ICH, affecting up to 6% with variable trial-dependent definitions), major extracranial hemorrhage, and angioedema (up to 5%).

Global Thrombolytic Drug Market Overview

Thrombolytics are provided in emergency situations to break up the thrombus (blood clot) that obstructs the affected artery in order to restore blood flow to the heart. In Canada, alteplase and tenecteplase are currently available for use. A thrombolytic is a synthetic form of tissue plasminogen activator, and it converts the plasminogen bound to fibrin clots to plasmin, which results in the degradation of the clot. Thrombolytic therapy has been a major advance in the management of acute myocardial infarction. Thrombolytic therapy works by lysing infarct artery thrombi and achieving reperfusion, thereby reducing infarct size, preserving left ventricular function, and improving survival.

Mechanical forces can be added to thrombolysis to reduce the therapy duration and improve efficacy on old thrombi. More and more endovascular thrombectomy devices are becoming commercially available, offering a wide variety of mechanical forces, including aspiration, rheolysis, rotational fragmentation, and ultrasounds. An example of a mechanical force frequently associated with thrombolysis in France is an attempt at thrombus aspiration before the start of the thrombolytic infusion. Attempting thrombus aspiration allows the bulk of the thrombus to lessen, thereby reducing treatment duration and the risk of distal embolization. An important downside of endovascular thrombectomy devices, however, is their high cost.

A disadvantage of thrombolysis that is inherent to its mechanism of action is the risk of bleeding. Therefore, a detailed examination of the patient is essential before the start of thrombolytic therapy to enable the exclusion of patients with contraindications to thrombolytic agents. This risk of bleeding depends on the dose of the thrombolytic agent that is being administered and is much less important for a single bolus injection (no significant increase in bleeding complications with a dose up to 500,000 IU urokinase administered as adjuvant to operative lower extremity revascularization16) than for a continuous infusion over several days.

The seamlessness that this process offers is almost unmatchable. The entire process is done under the purview of X-ray of imaging to get the correct site of the clot. Moreover, the technique is used for several treatments, which include thrombosis in the vascular bed, deep vein thrombosis, and thrombosis of dialysis fistuli. This is expected to increase the adoption of catheter-directed thrombolysis and make the entire process an essential form of stroke medication.

Global Thrombolytic Drug MarketSegmentation Analysis

The Global Thrombolytic Drug Market is segmented on the basis of Type, End User, Application, and Geography.

Thrombolytic Drug Market, By Type

  • Alteplase (Tissue Plasminogen Activator (tPA))
  • Reteplase
  • Urokinase
  • Streptokinase
  • Others

To Get a Summarized Market Report By Type-

Based on Type, the market is segmented into Alteplase (Tissue Plasminogen Activator (tPA)), Reteplase, Urokinase, Streptokinase, and Others. Alteplase (Tissue Plasminogen Activator (tPA)) accounted for the largest market share of 59.11% in 2022 and is projected to grow at the highest CAGR of 20.04% during the forecast period. Alteplase is a thrombolytic drug used in the treatment of various medical conditions characterized by the presence of blood clots. A recombinant tissue plasminogen activator (tPA) plays a crucial role in dissolving these clots and restoring normal blood flow. Alteplase converts plasminogen into plasmin, an enzyme that breaks down fibrin, a key component of blood clots. Its fibrinolytic action leads to the dissolution of the clot and the restoration of blood flow. Moreover, alteplase is typically administered intravenously by healthcare professionals. The specific dosage and administration regimen depends on the patient’s weight, the medical condition being treated, and the timing of treatment.

Thrombolytic Drug Market, By Application

  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Peripheral Arterial Occlusion
  • Stroke Acute Myocardial Infarction (AMI)

Based on Application, the market is segmented into Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Peripheral Arterial Occlusion, Stroke Acute Myocardial Infarction (AMI). Deep Vein Thrombosis (DVT) accounted for the largest market share of 33.97% in 2022 and is projected to grow at a CAGR of 16.28% during the forecast period. Deep vein thrombosis (DVT), or venous thrombosis, occurs when blood clots, or thrombi, form within the body’s deep veins. It typically happens due to either damage to the veins or the slowing down of blood flow within them. These clots have the potential to wholly or partially obstruct the average blood circulation in the affected vein. While DVTs most commonly manifest in the lower leg, thigh, or pelvis, they can also develop in other body regions, such as the arms, brain, intestines, liver, or kidneys.

Thrombolytic Drug Market, By End User

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Emergency Medical Services (EMS)
  • Homecare Settings
  • Research Institutions

Based on End User, the market is segmented into Hospitals and Clinics, Ambulatory Surgical Centers, Emergency Medical Services (EMS), Homecare Settings, and Research Institutions. Hospitals and Clinics accounted for the largest market share of 45.23% in 2022 and is projected to grow at a CAGR of 15.01% during the forecast period. Thrombolytic drugs are used in hospitals to treat patients experiencing ST-segment-elevation myocardial infarction (STEMI), a type of heart attack caused by a blood clot in a coronary artery. Administering thrombolytics promptly can dissolve the clot, restore blood flow to the heart, and minimize heart muscle damage. This time-sensitive treatment can be lifesaving when PCI (percutaneous coronary intervention) is not immediately available or feasible. Thrombolytic drugs are used in hospitals to treat severe cases of pulmonary embolism, where a blood clot has traveled to the lungs and is causing the significant blockage. Thrombolytics can dissolve the clot and improve blood flow in the pulmonary arteries, crucial for preventing further complications and reducing the risk of death.

Thrombolytic Drug Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

To Get a Summarized Market Report By Geography-

On the basis of Regional Analysis, the Global Thrombolytic Drug Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America accounted for the largest market share of 42.66% in 2022 and is projected to grow at a CAGR of 16.58% during the forecast period. Europe was the second-largest market in 2022 and it is projected to grow at a CAGR of 17.18%. The North American Thrombosis Forum (NATF) is a nonprofit organization incorporated by the Commonwealth of Massachusetts. NATF is dedicated to improving the lives of those affected by blood clots and related diseases. Through their comprehensive resources and innovative programming, they strive to educate patients and healthcare providers about thrombosis and its complications. Recombinant tissue plasminogen activator (tPA), approved for use in the United States for the treatment of acute ischemic stroke since 1996, improves overall outcomes from ischemic stroke when administered to selected patients.

In Europe, thrombolytic therapy for the dissolution of an occlusive coronary thrombus is a widely accepted approach to the management of acute myocardial infarction (AMI). Surveys conducted by the British Heart Foundation showed that 68% of consultant physicians and cardiologists in the United Kingdom routinely used thrombolysis to treat patients with AMI, and an additional 28% occasionally used such therapy. Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide evidence-based recommendations to assist physicians in their clinical decisions about intravenous thrombolysis for acute ischaemic stroke.

Key Players

The Global Thrombolytic Drug Market is highly fragmented with the presence of a large number of players in the market some of the major companies include Janssen Pharmaceuticals, Genentech, Bayer AG, AbbVie Inc., Sanofi, Boehringer-Ingelheim, CSL Behring, Biogen, Chiesi Pharmaceuticals, Lupin Limited, CIPLA, Ekr Therapeutics, Sedico Pharmaceuticals, Syner- Medica, Microbix Biosystems and others. This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Company Market Ranking Analysis

The company ranking analysis provides a deeper understanding of the top 3 players operating Thrombolytic Drug Market. takes into consideration several factors before providing a company ranking.

The top three players for the Thrombolytic Drug Market are Janssen pharmaceuticals, Genentech, and Bayer AG. The factors considered for evaluating these players include company’s brand value, product portfolio (including product variations, specifications, features, and price), company presence across major regions, product-related sales obtained by the company in recent years, and its share in the total revenue. further study the company’s product portfolio based on the technologies adopted or new strategies undertaken by the company to enhance their market presence globally or regionally. We also consider the distribution network (online as well as offline) of the company that helps us to understand the company’s presence and foothold in various Thrombolytic Drug Markets.

Company Regional Footprint

The company’s regional section provides geog

Table of Content

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

List Tables Figures

To get a detailed Table of content/ Table of Figures/ Methodology Please contact our sales person at ( chris@marketinsightsresearch.com )

FAQ'S

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@marketinsightsresearch.com

Within 24 to 48 hrs.

You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email